Acquisition includes abelacimab, a Factor XI-inhibiting monoclonal antibody in development for stroke prevention in patients ...
UBS analyst Matthew Weston downgraded Novartis (NVS) to Neutral from Buy with a price target of CHF 104, down from CHF 111. The firm believes ...
In this week's InnovationRx newsletter, federal judges halt Trump's cuts to NIH research payments, rural hospitals' ongoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback